RxDoctor Payments Data

Michael Bougoulias, MD

Family Medicine · Lake Mary, FLNPI 1174514178

Payments from drug & device makers

$9,801in general payments, 2019–2025

Across 450 payments — averaging $21.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$1K
  • Boehringer Ingelheim$1K
  • AbbVie$996
  • Novo Nordisk$974
  • AstraZeneca$547
  • Lilly USA, LLC$547
  • plus $4K from 44 others

What the payments were for

  • Travel & lodging$94110%
  • Food & beverage$8,60788%
  • Education$2533%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,801 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$100,421
Medicare patients
364
Services billed
1,681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin96$99,956
MounjaroTirzepatide56$76,555
TrulicityDulaglutide48$75,435
OzempicSemaglutide75$75,310
EliquisApixaban24$26,858
Repatha SureclickEvolocumab17$25,923
JanuviaSitagliptin Phosphate25$21,957
RybelsusSemaglutide17$17,490
FarxigaDapagliflozin Propanediol12$10,138
Breo ElliptaFluticasone/Vilanterol17$9,373
Rosuvastatin Calcium451$5,820
Atorvastatin Calcium398$3,729
Levothyroxine Sodium349$3,284
Ezetimibe107$3,168
SynthroidLevothyroxine Sodium42$2,880

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$547$151,989104 claims
Boehringer IngelheimJardiance$1,006$99,95696 claims
Novo NordiskOzempic, Rybelsus$974$92,80092 claims
PfizerEliquis$242$26,85824 claims
MerckJanuvia$32$21,95725 claims
AstraZenecaFarxiga$547$10,13812 claims
GSKBreo Ellipta$251$9,37317 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$43$3,284349 claims
AbbVieSynthroid$996$2,88042 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Lake Mary

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →